International news in seven languages
Topic
Scientists found that immune cells contributing to Alzheimer’s-related brain damage may be activated in lymph nodes outside the brain before traveling into the nervous system. Blocking this pathway in mice dramatically reduced neurodegeneration and preserved cognitive abilities, pointing to a potentially more accessible treatment target.
A large health-record analysis found that glucosamine use was associated with a 25% higher likelihood of mild cognitive impairment progressing to dementia. Lab experiments suggest the popular joint supplement may intensify an abnormal sugar-tagging process in the Alzheimer’s brain, although researchers say clinical trials are needed to determine whether it actually causes harm.
It is a disease that affects nearly 1.5 million people here in France. We met Virginie Grimaldi, one of the most read French writers. She gives us her testimony.
Alzheimer's disease affects nearly one million five hundred thousand people in France, a figure that could double by 2050. This Monday, September 21st is World Alzheimer Day, an opportunity to look at new tools available to patients such as robots or artificial intelligence that simulate familiar voices.
Scientists found that the 3D organization of DNA is disrupted in several types of brain cells affected by Alzheimer’s disease, altering how important genes are switched on and off. The discovery reveals a previously underexplored layer of the disease that could open new paths for understanding and eventually treating Alzheimer’s.
Scientists have uncovered sweeping changes in how the human brain controls and organizes its genome beginning in midlife, offering new clues to why aging sharply increases the risk of Alzheimer’s and other neurodegenerative diseases. One of the biggest shifts occurred between about ages 50 and 75, when many of the brain’s original immune cells declined and were replaced by cells with more inflammatory characteristics. Researchers also found weakening of cells that help maintain the blood-brain barrier, along with widespread deterioration in the genome’s three-dimensional organization.
Newer blood thinners may do more than prevent strokes in people with Alzheimer’s disease and atrial fibrillation. Researchers found that patients taking NOACs experienced a slower decline in cognitive function than those using warfarin or no blood thinners. The effect was modest each year but could add up over time.
